In a note RBC regards yesterday’s selloff in biotechs as an “especially attractive entry point” for leading names such names as Gilead Sciences (GILD -2.1%), Sarepta Therapeutics (SRPT -1.8%) and Constellation Pharmaceuticals (CNST -5.0%).
Analysts, led by Brian Abrahams, believe GILD could head back toward the $80s citing its “increasingly cohesive” oncology strategy and potential upside on breast cancer antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy).
RBC remains a “believer” in SRPT’s DMD gene therapies, looking forward to microdystrophin data in Q1 2021.
CNST does not reflect the “degree of de-risking” or long-term upside for lead BET inhibitor CPI-0610 which may improve upon Incyte’s (INCY -2.2%) Jakafi (ruxolitinib) in myelofibrosis.
GILD, SRPT and CNST are 26%, 19% and 65%, respectively, off their 52-week highs.
https://seekingalpha.com/news/3615888-buy-dip-in-biotechs-rbc
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.